Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 + HX008 in HER2-expressing locally advanced or metastatic urothelial carcinoma
ChiCTR2600124867Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRG002 and pucotenlimab in transitional cell carcinoma (TCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Recommended Phase 2 Dose (RP2D) and Objective Response Rate (ORR). Started May 2026; status: completed.
02
Drugs
MRG002pucotenlimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2600124867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124867.